Skip to main content
. Author manuscript; available in PMC: 2018 May 30.
Published in final edited form as: Eur J Pharm Sci. 2017 Feb 24;103:52–59. doi: 10.1016/j.ejps.2017.02.011

Fig 3. Principal component analysis of datasets.

Fig 3

The principal component analysis of the calculated molecular features for the MRP3 inhibitor dataset used to develop the Bayesian model and the FDA-approved dataset that was virtually screened. The plot demonstrates that the MRP3 inhibition training and test sets occupy a similar chemical space to a majority of the virtually screened dataset.